CD44 and breast cancer: The migratory potential of the sorted CD24+‐breast cancer cells and CD24−/CD44+‐breast CSC populations in the presence of combinatorial treatment of Doxorubicin low dose (0.01 μM) and compound 1e (5 μM) was observed to be significantly reduced as compared to the positive control group (10% FBS) (Figure 3B).